Status:
UNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Breast Cancer
Ovarian Cancer
Eligibility:
FEMALE
18-80 years
Brief Summary
This study aimed to compare the activity of Thymidine Kinase 1 in serum of two groups of woman at high and normal risk for breast/ovary cancer.
Detailed Description
Hereditary breast/ovarian cancer syndrome is associated with mutations in tumor suppressor BRCA1 and BRCA2 genes. Products of these genes play an important role in the repair of DNA double-strand brea...
Eligibility Criteria
Inclusion
- women from family with more than two breast cancer cases and one or more cases of ovarian cancer diagnosed at any age;
- women from family with more than three breast cancer cases diagnosed before the age 50;
- women from family withsister pair in which one of the following combinations was diagnosed before the age of 50: two breast cancers, two ovarian cancers, or a breast and ovarian cancer.
Exclusion
- •
- pregnant women;
- women with generalized CMV and HZV infections;
- women with severe B12 deficiency and megaloblastic anaemia;
- women with severe rheumatoid arthritis.
Key Trial Info
Start Date :
March 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2011
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00855998
Start Date
March 1 2009
End Date
March 1 2011
Last Update
June 3 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel, 91120